TwinBeech Capital’s aTyr Pharma ATYR Stock Holding History

TwinBeech Capital’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-21,434	Closed	-$64.7K	–	1027
2025 Q1	$64.7K	Buy	+21,434	New	+$78.2K	﹤0.01%	679

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TwinBeech Capital's ATYR Position: Q2 2025 in Review

TwinBeech Capital sold out of aTyr Pharma (ATYR) in Q2 2025, closing a stake of 21,434 shares — an estimated $64.7K sold.

TwinBeech Capital first reported a position in ATYR in Q1 2025 and held it in 1 quarter. The position peaked at $64.7K in Q1 2025. 110 funds tracked by Wall St. Rank hold ATYR as of Q2 2025.

TwinBeech Capital reported no remaining aTyr Pharma position as of Q2 2025 after selling out during the quarter.
TwinBeech Capital sold 21,434 aTyr Pharma shares in Q2 2025, an estimated $64.7K.
TwinBeech Capital first reported a position in aTyr Pharma in Q1 2025 and held it in 1 quarter.
TwinBeech Capital's aTyr Pharma position peaked at $64.7K in Q1 2025.
110 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2025.

Based on TwinBeech Capital's 13F filing for Q2 2025, filed 14 Aug 2025.